Otsuka Sues FDA Over Approval Of Abilify Maintena Rival
Otsuka Pharmaceutical Co. Ltd. is suing in D.C. federal court over the U.S. Food and Drug Administration's approval of a rival version of its schizophrenia drug Abilify Maintena, alleging that "regulatory...To view the full article, register now.
Already a subscriber? Click here to view full article